The Cochrane Collaboration completed a review entitled “Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) for the Prevention of Migraine in Adults” in 2015. In the review, they acknowledge that poor-quality research and low levels of evidence make it difficult to draw definitive conclusions, but then state that “A randomised controlled trial comparing a SSRI or a SNRI versus another drug or another non-pharmacological intervention is not a priority in the migraine research pipeline and might not exert a significant impact on the overall evidence”. A detailed evaluation of 10 of the 11 papers analysed in the Cochrane Review reveals that 9 of them use the International Classification of Headache Disorders (ICHD) system to determine their study cohorts. Despite being the current globally accepted standard for classification, diagnosis and categorization of migraine, the ICHD criteria are based on an arbitrary symptom list and offer little, if any, insight into the possible mechanisms involved in the pathophysiology of a migraine. Using the ICHD system in scientific studies which investigate the prevention and treatment of migraines, including those analyzed by the 2015 Cochrane Review, therefore results in amorphous cohort selection for those studies. This directly impacts the clinical relevance of the results drawn from the research. We acknowledge, and are grateful for, the important and highly credible contribution that the Cochrane Collaboration brings to our body of scientific knowledge. We are, however, concerned that the conclusions drawn in this important review might negatively impact on clinician ability to help individual migraine patients, not through any fault of the Cochrane Collaboration review system, but due to a fundamental flaw in the classification of migraines.
References
[1]
Banzi, R., Cusi, C., Randazzo, C., Sterzi, R., Tedesco, D. and Moja, L. (2015) Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) for the Prevention of Migraine in Adults. http://www.cochrane.org/CD002919/SYMPT_selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-norepinephrine-reuptake-inhibitors-snris
[2]
Bulut, S., Berilgen, M.S., Baran, A., Tekatas, A., Atmaca, M. and Mungen, B. (2004) Venlafaxine Versus Amitriptyline in the Prophylactic Treatment of Migraine: Randomized, Doubleblind, Crossover Study. Clinical Neurology and Neurosurgery, 107, 44-48. https://doi.org/10.1016/j.clineuro.2004.03.004
[3]
Steiner, T.J., Ahmed, F., Findley, L.J., MacGregor, E.A. and Wilkinson, M. (1998) S-Fluoxetine in the Prophylaxis of Migraine: A Phase II Double-blind Randomized Place-bo-Controlled Study. Cephalalgia, 18, 283-286.
https://doi.org/10.1046/j.1468-2982.1998.1805283.x
[4]
Tarlaci, S. (2009) Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache without Mood Disorders. Clinical Neuropharmacology, 32, 254-258. https://doi.org/10.1097/WNF.0b013e3181a8c84f
[5]
Schroeder, B.M. (2003) AAFP/ACP-ASIM Release Guidelines on the Management and Prevention of Migraines. The American Academy of Family Physicians. http://www.aafp.org/afp/2003/0315/p1392.html#
[6]
Silberstein, S.D., Holland, S., Freitag, F., Dodick, D.W., Argoff, C. and Ashman, E. (2012) Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults. Neurology, 78, 1337-1345. https://doi.org/10.1212/WNL.0b013e3182535d20
[7]
MacGregor, E.A., Steiner, T.J. and Davies, P.T.G. (2010) Guidelines for All Healthcare Professionals in the Diagnosis and Management of Migraine, Tension-Type Headache, Cluster Headache and Medication-overuse Headache. British Association for the Study of Headache. 3rd Edition (1st Revision), 1-53.
[8]
Pringsheim, T., Davenport, W.J. and Mackie, G. (2012) Canadian Headache Society Guideline for Migraine Prophylaxis. Canadian Journal of Neurological Sciences, 39, 17.
[9]
Evers, S., Afra, J., Frese, A., Goadsby, P.J., Linde, M., May, A. and Sándor, P.S. European Federation of Neurological Societies (2009) EFNS Guideline on the Drug Treatment of Migraine—Revised Report of an EFNS Task Force. European Journal of Neurology, 16, 968-981. https://doi.org/10.1111/j.1468-1331.2009.02748.x
[10]
Moja, L., Cusi, C., Sterzi, R.R. and Canepari, C. (2005) Selective Serotonin Re-uptake Inhibitors (SSRIs) for Preventing Migraine and Tension-type Headaches.
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002919.pub2/full
[11]
Banzi, R., Cusi, C., Randazzo, C., Sterzi, R., Tedesco, D. and Moja, L. (2015b) Selective Serotonin Reuptake Inhibitors (SSRIs) and Seroto-nin-norepinephrine Reuptake Inhibitors (SNRIs) for Preventing Tension-type Headache. www.cochrane.org/CD011681/SYMPT_selective-serotonin-reuptake-inhibitors-ssris-and-serotonin-norepinephrine-reuptake-inhibitors-snris
[12]
Polisca, R., Signoretti, P. and Marchi, P. (1992) Fluoxetine in the Treatment of Migraine with Interval Headache [La fluoxetina nella terapia della emicrania con cefalea intervallare]. Rassegna Internazionale di Clinica e Terapia, 72, 408-415.
[13]
Adly, C., Straumanis, J. and Chesson, A. (1992) Fluoxetine Prophylaxis of Migraine. Headache, 32, 101-104.
https://doi.org/10.1111/j.1526-4610.1992.hed3202101.x
[14]
Bank, J. (1994) A Comparative Study of Amitriptyline and Fluvoxamine in Migraine Prophylaxis. Headache, 34, 476-478. https://doi.org/10.1111/j.1526-4610.1994.hed3408476.x
[15]
Colucci d’Amato, C., Pizza, V., Marmolo, T., Giordano, E., Alfano, V. and Nasta, A. (1999) Fluoxetine for Migraine Prophylaxis: ADouble-blind Trial. Headache, 39, 716-719.
https://doi.org/10.1046/j.1526-4610.1999.3910716.x
[16]
Krymchantowski, A.V., Silva, M.T., Barbosa, J.S. and Alves, L.A. (2002) Amitriptyline versus Amitriptyline Combined with Fluoxetine in the Preventative Treatment of Transformed Migraine: A Double-Blind Study. Headache, 42, 510-514. https://doi.org/10.1046/j.1526-4610.2002.02125.x
[17]
Landy, S., McGinnis, J., Curlin, D. and Laizure, S.C. (1999) Selective Serotonin Reuptake Inhibitors for Migraine Prophylaxis. Headache, 39, 28-32. https://doi.org/10.1046/j.1526-4610.1999.3901028.x
[18]
Oguzhanoglu, A., Sahiner, T., Kurt, T. and Akalin, O. (1999) Use of Amitriptyline and Fluoxetine in Prophylaxis of Migraine and Tension-Type Headaches. Cephalalgia, 19, 531-532.
https://doi.org/10.1046/j.1468-2982.1999.019005531.x
[19]
Ozyalcin, S.N., Talu, G.K., Kiziltan, E., Yucel, B., Ertas, M. and Disci, R. (2005) The Efficacy and Safety of Venlafaxine in the Prophylaxis of Migraine. Headache, 45, 144-152.
https://doi.org/10.1111/j.1526-4610.2005.05029.x
[20]
International Headache Society (2018) The International Classification of Headache Disorders. 3rd Edition.
http://ichd-3.org/
[21]
International Headache Society (1988) IHS Classification ICHD-II.
http://www.ihs-klassifikation.de/en/01_einleitung/01_vorwort_auflage2/00.00.00_vorwort1aufl.html
[22]
Olesen, J. (2004) The International Classification of Headache Disorders. Cephalalgia, 24, 1-160.
[23]
Spierings, E.L. (2001) Migraine, Big and Small. Headache, 41, 918-922.
https://doi.org/10.1046/j.1526-4610.2001.041009918.x
[24]
Olesen, J. and Lipton, R.B. (1994) Migraine Classification and Diagnosis. International Headache Society Criteria. Neurology, 44, S6-S10.
[25]
International Headache Society (2013) The International Classification of Headache Disorders. 3rd Edition.
http://beta.ichd-3.org/
[26]
Shevel, E. and Shevel, D. (2014) The International Headache Society Classification of Migraine Headache—A Call for Substantiating Data. Journal of Biomedical Science and Engineering, 7, 112-114.
https://doi.org/10.4236/jbise.2014.73015
[27]
Bakal, D.A. and Kaganov, J.A. (1977) Muscle Contraction and Migraine Headaches, Psycophysiologic Comparison. Headache, 17, 208-215. https://doi.org/10.1111/j.1526-4610.1977.hed1705208.x
[28]
Friedman, A.P., Von Storch, T.J. and Merritt, H.H. (1954) Migraine and Tension Headaches: A Clinical Study of Two Thousand Cases. Neurology, 4, 773-788. https://doi.org/10.1212/WNL.4.10.773
[29]
Olesen, J. (1978) Some Clinical Features of the Acute Migraine Attack. An Analysis of 750 Patients. Headache, 18, 268-271. https://doi.org/10.1111/j.1526-4610.1978.hed1805268.x
